European Psychiatry - Volume 41 - April 2017

391 / 916

25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404 S387
EW0814
Efficacy of F17464, a new preferential
D3 antagonist in a placebo-controlled
phase 2 study of patients with an
acute exacerbation of schizophrenia
I. Bitter , M. Groc , C. Delsol , C. Fabre , M. Fagard , L. Barthe ,
F. Gaudoux , V. Brunner , F. Brackman , F. Tonner ∗
Institut de recherche Pierre-Fabre, France
∗ Corresponding author.
Introduction F17464 is a new highly potent preferential D3
antagonist, 5-HT1A and weak D2 partial agonist, with confirmed
antipsychotic-like activity in animal models. In healthy volunteers,
F17464 had a good safety and tolerability profile. A PET-scan study
determined a high D3 occupancy rate up to 22 h after a single dose.
Objectives The primary objective was to evaluate the efficacy of
40mg/day of oral F17464 in comparison to placebo.
Methods This double-blind, parallel group, multicenter study
included patients with acute exacerbation of schizophrenia treated
for 6 weeks as antipsychotic monotherapy. Patients were hos-
pitalised for the first 3 weeks of treatment, then continued as
outpatients.
Results The 144 randomized patients had a baseline PANSS mean
(SD) total score was 89.6 (9.5). The change from baseline of PANSS
total score to Day 43 on the FAS (LOCF), showed a statistically sig-
nificant difference in favor of F17464 over placebo: adjusted mean
(SE) change −13.5 (2.1) on F17464 and −7.8 (2.2) on placebo with
a treatment effect estimate −5.7 (2.7). The 20% or 30% response
rate was statistically higher in the F17464 group (47.2% and 25.0%)
compared to the placebo group (30.6% and 13.9%). The incidence
of treatment-emergent adverse events was slightly higher in the
F17464 group (70.8%) than in the placebo group (62.5%). There
were no clinically-relevant hepatic, metabolic, or cardiovascular
abnormalities. No EPS was reported under F17464.
Conclusion This is the first D3 antagonist that proves efficacy. The
results of this phase 2 study also demonstrate the favorable safety
profile of F17674 when compared to placebo.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0815
Stigma in early detection of psychosis:
Subjective experiences of those
concerned
M. Uttinger ∗, C. Rapp , E. Studerus , K. Beck ,
A. Riecher-Rössler
1 Psychiatric Services Solothurn, Ambulatorium, Olten, Switzerland
2 Psychiatric Services Solothurn, Center for the treatment of psychotic
disorders, Solothurn, Switzerland
3 University of Basel Psychiatric Hospital, Center for Gender Research
an Early Detection, Basel, Switzerland
∗ Corresponding author.
Introduction Despite the large scientific debate concerning
potentially stigmatizing effects of informing an individual about
being in an at-riskmental state (ARMS) for psychosis, studies inves-
tigating this topic are rare and quantitative assessment of this kind
of stigmatization does not exist so far.
Objectives This study presents first results regarding potentially
helpful or stigmatizing effects of being informed about an ARMS
assessed with a newly developed quantitative self-rating (FePsy-
Stigma questionnaire).
Methods Forty ARMS patients participating in the prospective
Basel Early Detection of Psychosis (FePsy) study as well as patients
clinically assessed in the early detection service of the Psychiatric
Services of Solothurn, completed the FePsy-Stigma questionnaire
during their follow-up assessments at least six months after they
had been informed about their increased risk of developing psy-
chosis. The questionnaire was constructed based on a previous
qualitative study and on adapted versions of formerly used instru-
ments for assessing stigma in mental health (Internalized Stigma
of Mental Illness Scale, Personal Beliefs and Experiences Question-
naire).
Results Stigmatization appeared to be low overall except for
social withdrawal due to suspected stigma. Stigma resistance,
stereotype awareness and expected discrimination scored consid-
erably higher than actually experienced discrimination, alienation
and stereotype endorsement.
Conclusions The results suggest that early detection services
help individuals cope with symptoms and build certain resilience
toward potential stigmatization, rather than enhancing or causing
the latter. In line with previous studies, our results indicate that
there is a considerable difference between expected and actually
experienced discrimination as well as between stereotype aware-
ness and stereotype endorsement.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0816
Sex-specific effect of intranasal
vasopressin, but not oxytocin, on
emotional recognition and perception
in schizophrenia patients
L. Vadas ∗, B. Bloch , R. Levin , I. Shalev , S. Israel ,
F. Uzefovsky , R. Bachner-Melman , A. Reshef , R.P. Ebstein ,
I. Kremer
1 Emek Medical Center, Psychiatry Department, Haifa, Israel
2 Herzog Memorial Hospital, Psychology Department, Jerusalem,
Israel
3 Hadassah Medical School, Hebrew University, Neurobiology
Department, Jerusalem, Israel
4 Hebrew University of Jerusalem, Psychology Department, Jerusalem,
Israel
5 National University of Singapore, Psychology Department,
Singapore, Singapore
6 Flügelman’s Mazor Mental Health Medical Center, Mental Health
Medical Center, Acre, Israel
∗ Corresponding author.
Background Impairments in social behavior and cognition, such
as the ability to identify others’ emotional state, are important fea-
tures in schizophrenia. Arginine vasopressin (AVP) and oxytocin
(OXT) and are nonapeptides that influence social cognition and
behavior. Previous studies have shown that the administration of
intranasal AVP or OXTmay affect the ability to recognize facial emo-
tions. The primary objective of this study was to investigate the
effects of a single dose of AVP or OXT on social cognition in patients
with schizophrenia. The secondary objective of the studywas to test
for sex-specific effects of intranasal AVP and OXT administration on
social cognition.
Methods In this double-blind, placebo-control, cross-over study,
34 patients diagnosed with schizophrenia or schizo-affective dis-
order, received a dose of AVP, OXT or placebo in three separate
meetings. Forty-five minutes after administration, subjects per-
formed facial emotion recognition tasks.
Results There were no significant main effects of hormone
administration on the ability to recognize facial emotions between
treatment conditions. However, AVP administration resulted in
sex-specific differences in emotion recognition. Specifically, in
men, AVP administration reduced the ability to recognize angry
faces. In women, AVP administration reduced the ability to recog-
nize sad faces and improved the ability to recognize fearful faces.
Conclusions These findings indicate that intranasal AVP may
affect the recognition of facial emotions differently in men and